FDA approves Lisraya for dermatomyositis in adults
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as the first oral treatment for dermatomyositis in adults.
8 hours ago
0
1
Skin and Connective Tissue Diseases: News and Research on Dermatomyositis
MeSH tree: C17.300.250
AAD: Significant benefits seen for brepocitinib 30 mg in dermatomyositis
For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a 30-mg dose compared with placebo, according to a study published online March 28 in ...
Apr 1, 2026
0
2
Current research may open doors to new treatments for children with juvenile dermatomyositis
Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH).
Sep 10, 2025
0
18
Skin issues can be first sign of rheumatological illnesses
Skin conditions may be the first sign that a person has a rheumatic disease that will also affect the joints, muscles or ligaments.
Apr 25, 2023
0
71
IV immune globulin bests placebo for dermatomyositis
Significantly more adults with dermatomyositis receiving intravenous immune globulin (IVIG) versus placebo have a response of at least minimal improvement, according to a study published in the Oct. 6 issue of the New England ...
Oct 6, 2022
0
33
Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis
A recent study in the Journal of Investigative Dermatology describes the success of using lenabasum, a cannabinoid receptor type 2 (CB2) agonist that triggers the resolution of inflammation, to treat amyopathic dermatomyositis. ...
Sep 21, 2022
0
81
